HRP20161713T1 - Derivat cikloalkana - Google Patents

Derivat cikloalkana Download PDF

Info

Publication number
HRP20161713T1
HRP20161713T1 HRP20161713TT HRP20161713T HRP20161713T1 HR P20161713 T1 HRP20161713 T1 HR P20161713T1 HR P20161713T T HRP20161713T T HR P20161713TT HR P20161713 T HRP20161713 T HR P20161713T HR P20161713 T1 HRP20161713 T1 HR P20161713T1
Authority
HR
Croatia
Prior art keywords
pain
oxy
pyrazol
benzenesulfonamide
pyrimidin
Prior art date
Application number
HRP20161713TT
Other languages
English (en)
Croatian (hr)
Inventor
Tsuyoshi Shinozuka
Hiroyuki Kobayashi
Sayaka SUZUKI
Kyosuke TANAKA
Hiroko KIMOTO
Yuki Domon
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of HRP20161713T1 publication Critical patent/HRP20161713T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20161713TT 2012-02-09 2013-02-08 Derivat cikloalkana HRP20161713T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012025754 2012-02-09
JP2012259122 2012-11-27
EP13746373.3A EP2813491B1 (en) 2012-02-09 2013-02-08 Cycloalkane derivative
PCT/JP2013/052985 WO2013118854A1 (ja) 2012-02-09 2013-02-08 シクロアルカン誘導体

Publications (1)

Publication Number Publication Date
HRP20161713T1 true HRP20161713T1 (hr) 2017-02-10

Family

ID=48947609

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161713TT HRP20161713T1 (hr) 2012-02-09 2013-02-08 Derivat cikloalkana

Country Status (30)

Country Link
US (3) US8889741B2 (OSRAM)
EP (2) EP3144300B1 (OSRAM)
JP (2) JP5997710B2 (OSRAM)
KR (1) KR20140127238A (OSRAM)
CN (1) CN104185629B (OSRAM)
AU (1) AU2013218592B2 (OSRAM)
BR (1) BR112014019478A2 (OSRAM)
CA (1) CA2864222C (OSRAM)
CO (1) CO7151511A2 (OSRAM)
CY (1) CY1118572T1 (OSRAM)
DK (1) DK2813491T3 (OSRAM)
ES (2) ES2659434T3 (OSRAM)
HR (1) HRP20161713T1 (OSRAM)
HU (2) HUE037048T2 (OSRAM)
IL (1) IL234014A (OSRAM)
IN (1) IN2014MN01577A (OSRAM)
LT (1) LT2813491T (OSRAM)
MX (1) MX349354B (OSRAM)
NZ (1) NZ628096A (OSRAM)
PH (2) PH12014501804A1 (OSRAM)
PL (1) PL2813491T3 (OSRAM)
PT (1) PT2813491T (OSRAM)
RS (1) RS55671B1 (OSRAM)
RU (1) RU2635354C2 (OSRAM)
SG (1) SG11201404707VA (OSRAM)
SI (1) SI2813491T1 (OSRAM)
SM (2) SMT201700053T1 (OSRAM)
TW (1) TWI612042B (OSRAM)
WO (1) WO2013118854A1 (OSRAM)
ZA (1) ZA201405801B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
BR112014010271A2 (pt) * 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
TW201400446A (zh) 2012-05-22 2014-01-01 Genentech Inc Ｎ－取代之苯甲醯胺及其使用方法
CA2878478A1 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
CN105263490B (zh) 2013-03-14 2018-05-22 基因泰克公司 取代的三唑并吡啶及其使用方法
CA2905613C (en) * 2013-03-14 2017-11-28 Daiichi Sankyo Company, Limited Drug for respiratory diseases
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
KR20180067561A (ko) 2015-09-28 2018-06-20 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
US10316026B2 (en) 2015-11-06 2019-06-11 Daiichi Sankyo Company, Limited Method for removing dimethoxybenzyl group
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
ES3022639T3 (en) * 2016-05-20 2025-05-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
CR20190236A (es) * 2016-10-17 2019-09-09 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10836758B2 (en) * 2016-10-27 2020-11-17 Bristol-Myers Squibb Company Acyl sulfonamide NaV1.7 inhibitors
JP7022751B2 (ja) * 2016-12-09 2022-02-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CA3076202A1 (en) 2017-09-20 2019-03-28 Abm Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
WO2019165290A1 (en) * 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
BR112021000209A2 (pt) 2018-08-31 2021-08-24 Xenon Pharmaceuticals Inc. Compostos de sulfonamida substituída por heteroarila e seu uso como agentes terapêuticos
EP3844158A1 (en) 2018-08-31 2021-07-07 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CN113164461A (zh) * 2018-12-26 2021-07-23 拉夸里亚创药株式会社 作为Nav1.7及Nav1.8阻断剂的杂环衍生物
US20240241265A1 (en) * 2023-01-18 2024-07-18 Qualcomm Incorporated Virtual positioning signal measurements

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
RU2007146769A (ru) * 2005-05-16 2009-06-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные и их применение в качестве модуляторов ионых каналов
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
EA020460B1 (ru) * 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
WO2012004714A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
EP2590972B1 (en) * 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
EP2590951B1 (en) * 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
BR112014010271A2 (pt) * 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives

Also Published As

Publication number Publication date
EP2813491B1 (en) 2016-11-02
LT2813491T (lt) 2017-02-10
CN104185629A (zh) 2014-12-03
MX2014009637A (es) 2015-06-23
SMT201700053T1 (it) 2017-03-08
TW201339152A (zh) 2013-10-01
WO2013118854A1 (ja) 2013-08-15
US20140045862A1 (en) 2014-02-13
HUE037048T2 (hu) 2018-08-28
PH12014501804B1 (en) 2014-11-17
EP2813491A4 (en) 2015-08-12
ZA201405801B (en) 2015-12-23
ES2659434T3 (es) 2018-03-15
RU2014136463A (ru) 2016-03-27
JPWO2013118854A1 (ja) 2015-05-11
NZ628096A (en) 2016-06-24
DK2813491T3 (en) 2017-02-13
RS55671B1 (sr) 2017-06-30
US8889741B2 (en) 2014-11-18
SI2813491T1 (sl) 2017-02-28
JP2017008093A (ja) 2017-01-12
PL2813491T3 (pl) 2017-08-31
PH12015502675A1 (en) 2017-04-24
JP6154052B2 (ja) 2017-06-28
ES2613078T3 (es) 2017-05-22
KR20140127238A (ko) 2014-11-03
JP5997710B2 (ja) 2016-09-28
IL234014A0 (en) 2014-09-30
SMT201700053B (it) 2017-03-08
IL234014A (en) 2017-09-28
TWI612042B (zh) 2018-01-21
MX349354B (es) 2017-07-24
IN2014MN01577A (OSRAM) 2015-05-08
PT2813491T (pt) 2017-02-10
EP3144300B1 (en) 2017-12-20
AU2013218592A1 (en) 2014-09-18
US20150018551A1 (en) 2015-01-15
CY1118572T1 (el) 2017-07-12
CA2864222A1 (en) 2013-08-15
AU2013218592B2 (en) 2016-12-22
HK1203503A1 (en) 2015-10-30
CO7151511A2 (es) 2014-12-29
CN104185629B (zh) 2017-10-13
SG11201404707VA (en) 2014-10-30
US9493448B2 (en) 2016-11-15
EP3144300A1 (en) 2017-03-22
HUE031450T2 (en) 2017-07-28
BR112014019478A2 (pt) 2019-05-28
US9845313B2 (en) 2017-12-19
CA2864222C (en) 2016-10-25
US20170001984A1 (en) 2017-01-05
PH12014501804A1 (en) 2014-11-17
RU2635354C2 (ru) 2017-11-13
EP2813491A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
HRP20161713T1 (hr) Derivat cikloalkana
HRP20130935T1 (hr) Bicikliäśki derivat aminokiseline
MD20140037A2 (ro) Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
RU2016105436A (ru) Нейроактивные стероиды, композиции и их использование
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
JP2018505898A5 (OSRAM)
RU2014119711A (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
HRP20190815T1 (hr) Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret)
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
HRP20100677T1 (hr) IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
RU2014103587A (ru) Производные циклических аминов в качестве антагонистов рецептора ер4
MX348548B (es) Derivado heterociclico y farmaceutico.
PH12012502120B1 (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
CA2574600A1 (en) Pyridine derivatives
BR112019021868A2 (pt) Sal de um composto derivado de aminopiridina, forma cristalina do mesmo, e processo para a preparação do mesmo
CA2758474A1 (en) Novel p2x7r antagonists and their use
HRP20240173T1 (hr) Fluorofenil beta-hidroksietilamini i njihova upotreba u liječenju hiperglikemije
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
HRP20100573T1 (hr) Triazolopiridinkarboksamidni derivati, njihovo dobivanje i njihova upotreba u terapiji
MY184433A (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
HRP20191734T1 (hr) Pirimidinski derivati korisni kao selektivni jak3 i/ili jak1 inhibitori
MY206359A (en) Heteroaryl-substituted pyrazole compound and medicinal use thereof
PH12021551035A1 (en) Pyrazoles as modulators of hemoglobin
ZA201807393B (en) Treatment of neurological disorders